Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Vasilios Athans"'
Autor:
Joy Uzoma, Sonal Patel, Vasilios Athans, Shawn Binkley, Kathleen Degnan, Lauren Dutcher, Keith W Hamilton, Tiffany Lee, Steve Saw
Publikováno v:
Open Forum Infectious Diseases. 9
Background Approximately 15% of hospitalized patients are labeled as beta-lactam (BL) allergic. Despite this, it is estimated that > 90% of patients do not have clinically significant hypersensitivity reactions and are BL-tolerant. The BL allergy lab
Autor:
Elysia Burke, Desiree Croteau, Lauren Dutcher, Keith W Hamilton, Kathleen Degnan, Tiffany Lee, Steve Saw, Sonal Patel, Shawn Binkley, Vasilios Athans
Publikováno v:
Open Forum Infectious Diseases. 9
Background Outpatient parenteral antimicrobial therapy (OPAT) offers numerous clinical advantages, though adverse drug events (ADEs) are a common and potentially preventable challenge that may contribute to 30-day readmissions and other negative outc
Autor:
Thomas G. Fraser, Kaitlyn Rivard, Steven M. Gordon, Elizabeth Neuner, Vasilios Athans, Sandra S. Richter, Allison R. Riffle, Brian C Bohn
Publikováno v:
Journal of Pharmacy Practice. 35:541-545
Background: In September 2018, pharmacy antimicrobial stewardship (AMS) services were expanded to include weekends at this academic medical center. Activities performed by AMS pharmacists on the weekends include blood culture rapid diagnostic (RDT) r
Publikováno v:
Journal of Oncology Pharmacy Practice. :107815522311618
Introduction Rhizobium radiobacter is a gram-negative, opportunistic phytopathogen that rarely causes human infections. We report two cases of Rhizobium radiobacter central line-associated bloodstream infection (CLABSI) in allogeneic hematopoietic ce
Autor:
Veena Venugopalan, Abdalhamid M Lagnf, Lee Amaya, Kyle C Molina, Jinhee Jo, Michael P. Veve, David Allen, Stephen Saw, Kevin W. Garey, Taylor Morrisette, Michael J. Rybak, Susan L. Davis, Lilian M. Abbo, Kimberly C. Claeys, Travis J Carlson, Vasilios Athans, Jessica K. Ortwine, Sarah C J Jorgensen, Ana D Vega, Kailynn DeRonde, Wesley D Kufel, Marco R Scipione, Christine Yost, Ryan P. Mynatt, Jing J. Zhao, Mathew Miller, Sara Alosaimy
Publikováno v:
Open Forum Infectious Diseases
Background We aimed to describe the clinical characteristics and outcomes of patients treated with meropenem-vaborbactam (MEV) for a variety of gram-negative infections (GNIs), primarily including carbapenem-resistant Enterobacterales (CRE). Methods
Autor:
Gary W. Procop, Elizabeth A. Neuner, Andrea Pallotta, Kaitlyn Rivard, Samantha Loutzenheiser, Simon W. Lam, Pavithra Srinivas, Sandra S. Richter, Kristin Martinez, Vasilios Athans
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 39:709-717
OBJECTIVE Respiratory viral polymerase chain reaction (RV PCR) tests assist in rapidly identifying viral pathogens and differentiating viral versus bacterial causes of pneumonia. Studies evaluating the use of RV PCR tests on antibiotic use in adults
Autor:
Jessica Cunningham, Shawn Binkley, Tanya Uritsky, Stephen Saw, Sonal Patel, Tiffany Lee, Keith W Hamilton, Kathleen Degnan, Lauren Dutcher, Vasilios Athans
Publikováno v:
Open Forum Infectious Diseases
Background Suboptimal oral antibiotic prescriptions (OAPs) are prevalent at discharge and contribute to treatment failure, resistance, toxicity, and excess costs. Syndrome-specific prescribing patterns have not been widely described at discharge, nor
Publikováno v:
The International journal of artificial organs. 44(6)
Introduction: Hemodynamic derangements due to heart failure are associated with alterations in pharmacokinetics. Although use of mechanical circulatory support mitigates such derangements, little evidence is available regarding pharmacokinetics in pa
Publikováno v:
Transplant Infectious Disease. 23
Background Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug of choice for Pneumocystis jirovecii pneumonia (PJP) prophylaxis and has activity against other opportunistic infections (OIs) after solid organ transplant (SOT). We aimed to describe the
Autor:
Travis J Carlson, Veena Venugopalan, David Allen, Stephen Saw, Ryan P. Mynatt, Sarah C J Jorgensen, Vasilios Athans, Kevin W. Garey, Christine Yost, Sarah M Melvin, Abdalhamid M Lagnf, Sara Alosaimy, Michael J. Rybak, Susan L. Davis, Michael P. Veve
Publikováno v:
Open Forum Infectious Diseases
Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. M